

1 **Title:** Analysis of severe illness after post-vaccination COVID-19 breakthrough among adults with and
2 without HIV in the United States

3
4 **Authors:** Raynell Lang, MD MSc^{1,2}, Elizabeth Humes, MPH¹, Sally B. Coburn, PhD MPH¹, Michael A.
5 Horberg, MD, MAS³, Lily F Fathi, MPH³, Eric Watson, BA³, Celeena R Jefferson, MIT³, Lesley S. Park, PhD,
6 MPH⁴, Amy C. Justice, MD, PhD^{5,6,7}, Kirsha S. Gordon, PhD, MS^{6,7}, Kathleen M Akgün, MD MS^{6,7}, Sonia
7 Napravnik, PhD^{8,9}, Jessie K. Edwards, PhD, MSPH⁸, Lindsay E. Browne, BA⁹, Deana M. Agil, MR⁹, Michael
8 J. Silverberg, PhD, MPH¹⁰, Jacek Skarbinski MD^{10,11}, Wendy A. Leyden, MPH¹⁰, Cameron Stewart, MS¹,
9 Brenna C Hogan, MPH¹, Kelly A. Gebo, MD, MPH^{1,12}, Vincent C. Marconi^{13,14}, Carolyn F. Williams, PhD¹⁵,
10 and Keri N. Althoff, PhD MPH¹ for the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-
11 ACCORD of IeDEA

- 12
13 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
14 2. Department of Medicine, University of Calgary, Calgary, Canada
15 3. Kaiser Permanente Mid-Atlantic States, Mid- Atlantic Permanente Research Institute, Rockville, MD,
16 USA
17 4. Stanford Center for Population Health Sciences, Palo Alto, CA, USA
18 5. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
19 6. Department of Medicine, Yale School of Medicine, New Haven, CT, USA
20 7. VA Connecticut Healthcare System, West Haven, CT, USA
21 8. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
22 9. Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill,
23 NC, USA
24 10. Kaiser Permanente Northern California, Division of Research, Oakland CA, USA
25 11. Department of Infectious Diseases, Oakland Medical Center, Oakland CA, USA
26 12. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
27 13. Emory University School of Medicine and Rollins School of Public Health, Atlanta, GA, USA

28 14. Atlanta Veterans Affairs Medical Center, Decatur, GA, USA

29 15. Epidemiology Branch, Division of AIDS at National Institute of Allergy and Infectious Diseases

30 (NIAID), National Institute of Health (NIH), Rockville, MD, USA

31

32 **Corresponding author:**

33 Keri N Althoff, PhD, MPH
34 Associate Professor
35 Department of Epidemiology
36 Johns Hopkins Bloomberg School of Public Health
37 615 N Wolfe St, Rm E7142
38 Baltimore, MD 20295
39 kalthoff@jh.edu
40

41 **Keywords:** HIV, COVID-19, SARS-CoV-2, vaccination, breakthrough, hospitalization, severe illness

42

43

44

45 **Key Points:**

46 **Question:** In 2021, among fully vaccinated people with COVID-19 breakthrough illness, was the risk of
47 severe illness higher in people with HIV (PWH) compared to people without HIV (PWoH)?
48

48

49 **Findings:** PWH with <350 cells/mm³ have a 59% increased risk of severe breakthrough illness compared to
50 PWoH.
51

51

52 **Meaning:** Vaccinations effectively reduce the risk of severe COVID-19 infection in both PWH and PWoH;
53 however, PWH having a CD4 count <350 cells/mm³ are at higher risk of severe breakthrough infection
54 compared to PWoH. PWH with moderate immune suppression should be considered for additional vaccine
55 dosages and other risk-reduction measures.

56 **ABSTRACT**

57 **Importance:** Understanding the severity of post-vaccination COVID-19 breakthrough illness among people
58 with HIV (PWH) can inform vaccine guidelines and risk-reduction recommendations.

59
60 **Objective:** Estimate the rate and risk of severe breakthrough illness among vaccinated PWH and people
61 without HIV (PWoH) who experience a breakthrough infection.

62
63 **Design, setting, and participants:** The Corona-Infectious-Virus Epidemiology Team (CIVET-II)
64 collaboration consists of four US longitudinal cohorts from integrated health systems and academic centers.
65 Adults (≥ 18 years old), in-care, fully vaccinated by June 30, 2021 with HIV, and matched PWoH (on date fully
66 vaccinated, age group, race/ethnicity, and sex) were the source population. Those who experienced a post-
67 vaccination SARS-CoV-2 breakthrough infection were eligible. Severe COVID-19 breakthrough illness was
68 defined as hospitalization due to COVID-19. Discrete time proportional hazards models estimated adjusted
69 hazard ratios (aHR) and 95% confidence intervals ([,]) of severe breakthrough illness by HIV status adjusting
70 for demographics, COVID-19 vaccine type, and clinical factors. The proportion of patients requiring
71 mechanical ventilation or died was compared by HIV status.

72
73 **Exposure:** HIV infection

74
75 **Outcome:** Severe COVID-19 breakthrough illness, defined as hospitalization within 28 days after a
76 breakthrough SARS-CoV-2 infection with a primary or secondary COVID-19 discharge diagnosis.

77
78 **Results:** Among 1,241 PWH and 2,408 PWoH with breakthrough infections, the cumulative incidence of
79 severe illness in the first 28 days was low and comparable between PWoH and PWH (7.3% vs. 6.7%,
80 respectively, risk difference=-0.67% [-2.58%, 1.23%]). The risk of severe breakthrough illness was 59%
81 higher in PWH with CD4 counts < 350 cells/mm³ compared with PWoH (aHR=1.59 [0.99, 2.46]). In
82 multivariable analyses among PWH, being female, older, having a cancer diagnosis, and lower CD4 count

83 increased the risk of severe breakthrough illness, while previous COVID-19 reduced the risk. Among all
84 patients, 10% were mechanically ventilated and 8% died, with no difference by HIV status.

85

86 **Conclusions and Relevance:** The risk of severe COVID-19 breakthrough illness within 28 days of a
87 breakthrough infection was low among vaccinated PWH and PWoH. However, PWH with moderate and
88 severe immune suppression had a higher risk of severe breakthrough infection. Recommendations for
89 additional vaccine doses and risk-reduction strategies for PWH with moderate immune suppression may be
90 warranted.

91 **INTRODUCTION**

92 SARS-CoV-2 vaccination is an effective protective measure against coronavirus disease 2019
93 (COVID-19).¹⁻³ Although uncommon, people with HIV (PWH) have a higher risk for post-vaccination (i.e.
94 breakthrough) SARS-CoV-2 infection.⁴⁻⁹ Our prior study showed a 28% increased risk for breakthrough
95 SARS-CoV-2 infection in PWH compared to people without HIV (PWoH), although breakthrough cumulative
96 incidence was low (PWH=3.1%, PWoH=2.5%), consistent with findings among people with other
97 immunosuppressive conditions.^{4,5,9} Data on breakthrough COVID-19 illness, particularly severe illness
98 requiring hospitalization, in PWH remain sparse^{10,11}

99 Studies on the severity of breakthrough COVID-19 illness by HIV status are equivocal, some finding
100 comparable severity,¹²⁻¹⁵ while others have reported a higher risk of developing severe illness and worse
101 outcomes, including death, for PWH compared to PWoH.¹⁶⁻¹⁹ Immune dysfunction is believed to increase
102 severe COVID-19 illness risk in PWH, with lower CD4 counts and detectable HIV viral loads associated with
103 worse outcomes.^{20,21} A higher risk of severe illness in PWH may be confounded by the greater comorbidity
104 burden among PWH (compared to similar aged PWoH), including hypertension, diabetes, cardiovascular
105 disease, and smoking.^{22,23} Conversely, PWH have greater immune dysfunction and a lower likelihood of
106 hyperactive cytokine response, which may reduce the risk of severe illness in PWH.²² With global COVID-19
107 vaccination uptake, there is an increasing need to estimate severe COVID-19 breakthrough illness rates and
108 risk among PWH and an appropriate control group. However, large cohorts are needed to observe sufficient
109 breakthrough infections that progress to severe illness.

110 Current US Centers for Disease Control and Prevention (CDC)'s guidelines recommend risk
111 reduction behaviors (i.e. mask wearing), an additional COVID-19 primary series vaccine dose and second
112 booster dose for PWH having "advanced or untreated HIV infection."^{24,25} PWH having partially recovered
113 CD4 counts and moderate immune suppression are not currently recommended for an additional or second
114 booster dose. Our objective was to determine if HIV infection was associated with increased severe COVID-
115 19 outcomes among fully vaccinated adults with a breakthrough SARS-CoV-2 infection, and to determine the
116 risk factors for severe COVID-19 breakthrough illness among PWH.

117

118 **METHODS**

119 *Study population*

120 The Corona-Infectious-Virus Epidemiology Team (CIVET-II) cohort is comprised of four cohorts
121 including Kaiser Permanente Mid-Atlantic States (Maryland, District of Columbia, northern Virginia), Kaiser
122 Permanente Northern California, University of North Carolina Chapel Hill HIV Clinic (UNC), and the Veterans
123 Aging Cohort Study (VACS), a cohort of PWH (and similar PWOH) receiving care within the National US
124 Veterans Affairs Healthcare System. This collaboration is an extension of the North American AIDS Cohort
125 Collaboration on Research and Design.²⁶ Each local institution and the Johns Hopkins Bloomberg School of
126 Public Health institutional review board granted approval.

127 Adults (≥ 18 years old), “in-care” (**Supplement Table 1**), and fully vaccinated against COVID-19
128 between December 11, 2020 (Emergency Use Authorization of the first COVID-19 vaccine) and June 30,
129 2021, were eligible. Full vaccination status was defined using CDC criteria: a) 14 days after BNT162 (Pfizer)
130 or mRNA-1273 (Moderna) mRNA vaccine second dose; or b) 14 days after Janssen Ad26.COV2.S (J&J)
131 single dose.²⁷ Patients with vaccines not authorized in the US were excluded.

132 Fully vaccinated PWH were matched to three PWOH on the date fully vaccinated (± 14 days of the
133 PWH vaccination date), 10-year age group, race/ethnicity, and sex at birth. Race/ethnicity was included
134 given the disproportionate burdens of HIV by race/ethnicity. To maximize the cohort size, PWH could be
135 matched to individuals one age group above or below their category. If three matches were unavailable,
136 PWH were matched to one or two PWOH. The VACS (N=67,627) matches each Veteran with HIV to two
137 Veterans without HIV per their longstanding schema, based on age, race/ethnicity, sex, and clinical site at
138 cohort entry; VACS participants were not matched on date fully vaccinated.²⁸

139 Participants were eligible for the present study if they had breakthrough COVID-19, defined as the
140 first SARS-CoV-2 infection (detectable SARS-CoV-2 nucleic acid amplification assay [NAAT] or antigen
141 test) or COVID-19 diagnosis (International Classification of Diseases (ICD)-10 codes [**Supplement Table 2**])
142 after the date fully vaccinated. Additional detectable SARS-CoV-2 laboratory test results and/or diagnoses
143 occurring within ± 90 days of breakthrough were considered persistent infection.²⁹ If a COVID-19 diagnosis

144 code was also identified within the 90-day window of detectable result, the first laboratory test was the
145 breakthrough diagnosis date.

146 All variables were abstracted from electronic health records (EHR). Our study follows the
147 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

148
149 *Outcome: Severe COVID-19 breakthrough illness*

150 Severe COVID-19 breakthrough illness was defined as: 1) hospitalization within 28 days of
151 breakthrough; and 2) discharge diagnosis ranked first or second was COVID-19. All discharge diagnoses
152 were evaluated by two infectious disease physicians to exclude hospitalizations that were unlikely due to
153 COVID-19 (trauma, surgical, non-COVID-19 infections, mental health, or substance use admissions). Only
154 the first-ranked discharge diagnosis was available for one cohort (contributing 28% of the study population).
155 In this cohort, if COVID-19 was not the first-ranked discharge diagnosis, and there was ≥ 1 other discharge
156 diagnosis suggestive of COVID-19 (i.e., pneumonia due to coronavirus disease, other viral pneumonia, acute
157 respiratory failure, or hypoxemia) the patient was classified as the outcome of severe COVID-19
158 breakthrough illness.

159 Mechanical ventilation and extracorporeal membrane oxygenation (ECMO) procedures were
160 extracted from ICD-10 procedure and current procedural terminology (CPT) codes (**Supplement Table 2**)
161 occurring between the hospital admission and discharge dates. Death occurring during or within 30 days
162 following hospitalization or within 30 days following COVID-19 diagnosis among those not hospitalized was
163 extracted from EHR.

164
165 *Exposure: HIV infection*

166 PWH were identified using HIV registries or HIV ICD diagnosis codes (**Supplement Table 1**). PWOH
167 were classified as such if there was no evidence of HIV infection using these same sources as of December
168 11, 2020.

169
170 *Covariates*

171 Demographic covariates included age, race/ethnicity, and sex at birth. COVID-19 covariates included
172 the primary series vaccine type (Pfizer, Moderna, J&J), additional vaccine dose (receipt ≥ 28 days after
173 completion of primary series), and SARS-CoV-2 infection prior to date fully vaccinated (history of COVID-19).
174 History of COVID-19 included both infections occurring prior to any vaccination or in the window between the
175 first dose and full vaccination (partial breakthrough).

176 Comorbidity covariates included obesity (body mass index [BMI] ≥ 30 kg/m²), type 2 diabetes (DM),
177 hypertension (HTN), end-stage renal disease (ESRD), immune suppressive conditions (organ or tissue
178 transplantation [SOT], rheumatoid arthritis [RA], systemic lupus erythematosus [SLE]), cancer, and
179 pregnancy. Comorbidity diagnoses were identified using ICD-10 codes, measured closest to the date fully
180 vaccinated and after October 1, 2015; or January 1, 2020, for cancer and pregnancy only (see **Supplement**
181 **Table 2** for ICD-10 diagnosis codes).

182 Among PWH, CD4 T-cell count, and HIV-1 plasma RNA viral load suppression were collected closest
183 to the date of full vaccination after January 1, 2020, and at antiretroviral therapy initiation (12 months prior to
184 1 month after). HIV viral suppression was defined as < 50 copies/mL. History of AIDS diagnosis (clinical
185 diagnosis³⁰ or CD4 count < 200 cells/mm³) prior to date fully vaccinated was included.

186

187 *Statistical analysis*

188 Study entry was the date of observed breakthrough COVID-19. Individuals were followed to date of
189 severe breakthrough COVID-19 illness (outcome) or date of death, disenrollment from the health system
190 (applicable to 2 of the health systems), 28 days after breakthrough COVID-19, or December 31, 2021,
191 whichever occurred first.

192 Severe COVID-19 breakthrough illness monthly incidence rates (IR) per 100 person-years (PY) and
193 95% confidence intervals ([,]) were calculated by HIV status. Severe COVID-19 breakthrough illness
194 cumulative incidence was estimated from the date of breakthrough COVID-19 through day 28; estimates
195 were stratified by HIV status, and among PWH, CD4 count (< 350 , 350-499, and ≥ 500 cells/mm³) and viral
196 suppression status. Using the same timescale, cumulative incidence was also estimated by HIV status for
197 each vaccine type and for those who received an additional vaccine dose (≥ 28 days after primary series

198 completion and prior to breakthrough COVID-19). Log-rank tests were calculated to test for differences in
199 cumulative incidence and risk differences were estimated (with standard error or Wald 95% confidence
200 intervals).

201 A discrete time-to-event analysis using a complimentary log-log model estimated the unadjusted and
202 adjusted hazard ratios (aHR) with 95% confidence intervals for severe COVID-19 breakthrough illness risk by
203 HIV status. Adjustment factors included: sex, race/ethnicity, age, additional vaccine dose following primary
204 series, prior COVID-19, obesity, DM, HTN, ESRD, SOT, RA, SLE, cancer, and cohort. Subgroup analyses
205 stratified by HIV status allowed for investigations into risk factors for severe COVID-19 breakthrough illness
206 in both groups. Among PWH, prior AIDS diagnosis, HIV viral suppression and CD4 count were evaluated as
207 risk factors for severe COVID-19. Sensitivity analyses excluded participants without first or second diagnosis
208 code rankings.

209

210 RESULTS

211 Among 113,994 patients (33,029 PWH and 80,965 PWoH), there were 3,649 breakthrough COVID-
212 19 infections (1,241 PWH and 2,408 PWoH). Of those who experienced a COVID-19 breakthrough infection,
213 60% were ≥ 55 years, 89% were male, 47% were non-Hispanic Black, 59% received Pfizer and 31%
214 received Moderna for their primary series, and 15% received an additional COVID-19 vaccine dose ≥ 28 days
215 after primary series completion (20% in PWH and 13% in PWoH). PWH who had CD4 count of < 200
216 cells/mm³ (17%) and 200-349 cells/mm³ (16%) were less likely to receive an additional vaccine dose,
217 compared to PWH with CD4 counts ≥ 350 cells/mm³ (20%) (**Supplemental Table 3**). Among the N=3,649
218 patients with breakthrough COVID, the majority (75%) were laboratory confirmed and the remainder were
219 based on clinical diagnosis codes. Forty-nine percent of breakthroughs occurred during the Delta variant
220 (B.1.617.2) surge from July-Oct 2021, and 41% occurred from Nov-Dec 2021 (the start of the Omicron
221 variant [B.1.1.529] wave) (**Table 1**). PWH (compared with PWoH) had a lower proportion with obesity (36%
222 vs. 54%), DM (25% vs. 34%), and HTN (51% vs. 60%) prior to vaccination. The proportion with ESRD, RA,
223 SLE, or having received a SOT or a cancer diagnosis were similar by HIV status. Among PWH, 26% had

224 history of AIDS prior to vaccination, 91% were virally suppressed and median CD4 count was 620
225 (interquartile range [IQR]: 438, 846) cells/mm³ at the time fully vaccinated.

226 Among those with breakthrough COVID-19, 249 (7% overall; 79 or 6% of PWH; 170 or 7% PWOH)
227 had severe COVID-19 breakthrough illness and were hospitalized (**Table 1** and **Supplement Figure 1**). Most
228 (66%) hospitalizations occurred on the same day, and 81% occurred within two days following COVID-19
229 diagnosis. The median duration of hospitalization was 5 (IQR: 3, 8) days among PWOH and 4 (IQR: 2, 8)
230 days among PWH. Among all hospitalized patients 10% were mechanically ventilated (**Table 1**). There were
231 33 deaths (1% overall; 12 or 1% in PWH; 21 or 1% in PWOH) that occurred during or within 30 days of
232 hospital discharge or COVID-19 diagnosis. **Supplement Table 4** describes characteristics stratified by HIV
233 status and severe COVID-19 breakthrough illness status.

234

235 *Incidence Rates (IR) and Cumulative Incidence of Severe COVID-19 Breakthrough Illness*

236 The IR of severe COVID-19 breakthrough illness was higher among PWOH (138 [118, 160] /100 PY)
237 versus PWH (117 [92, 145] /100 PY) (**Figure 1**) and relatively stable over time (**Figure 1, Supplement Table**
238 **5**) with slight fluctuations reflecting the bimodal distribution of the Delta and Omicron variant waves
239 (**Supplement Figure 2**).

240 The 28-day severe COVID-19 breakthrough illness cumulative incidence was similar among PWOH
241 (7.3% [6.3%, 8.4%]) versus PWH (6.7% [5.2% 8.1%]), log rank p=0.399, risk difference=-0.67% [-2.58%,
242 1.23%]) (**Figure 2a**). PWH with lower CD4 counts (<350 cells/mm³) at full vaccination had a higher risk of
243 severe COVID-19 breakthrough illness compared with both PWOH and PWH with CD4 counts vs. ≥350
244 cells/mm³ (**Figure 2b, Supplement Figure 3**). Risk did not differ by HIV viral load (Figure 2c).

245 Severe COVID-19 breakthrough illness risk was highest among patients with J&J for their primary
246 vaccine series (9.3% [6.1, 12.4%]), followed by Pfizer (7.2% [6.1%, 8.3%]) and Moderna (6.2% [4.8%, 7.7%])
247 (**Figure 3a**), with no statistically significant differences by HIV status within each vaccine group. Regardless
248 of the primary vaccine series type, having an additional dose reduced the risk of severe COVID-19
249 breakthrough illness in both PWH and PWOH (log-rank p=0.021, **Figure 3b**)

250

251 *Risk factors for Severe COVID-19 Breakthrough Illness, by HIV status*

252 There was no difference in severe COVID-19 breakthrough illness risk in PWH vs. PWoH (aHR=1.02
253 [0.76, 1.35]); however, there was a 59% increased risk among PWH having a CD4 count <350 cells/mm³
254 compared with PWoH (aHR=1.59 [0.99, 2.46], **Table 2**). Stratified by HIV status, PWH and PWoH had an
255 increased risk of severe COVID-19 breakthrough illness with increasing age and decreased risk among
256 those with an additional vaccine dose.

257 Among PWH, severe COVID-19 breakthrough illness risk increased with decreasing CD4 count
258 (compared to CD4 ≥500 cells/mm³: 200-349 cells/mm³ aHR=1.65 [0.80, 3.21]; <200 cells/mm³ aHR=2.57
259 [1.15, 5.29]; **Table 2**). Female PWH had a nearly 3-fold increased severe COVID-19 breakthrough risk
260 compared to males. Increased risk associated with non-Hispanic Black and Hispanic race/ethnicity and
261 comorbidities ranged from 12% to 54% (p>0.05). Having a cancer diagnosis was associated with nearly 2-
262 fold increased risk of severe COVID-19 breakthrough illness (aHR=1.97 [1.05, 3.51]).

263 Among PWoH, females had a reduced risk of severe COVID-19 breakthrough illness compared with
264 males (p>0.05, **Table 2**). There was no observed difference in risk by race, obesity, DM, RA, SLE or having a
265 cancer diagnosis; but there was a 4.5-fold (aHR=4.51 [2.35, 9.80]) increased risk with HTN and 2.5-fold
266 increased risk with ESRD (aHR=2.53 [1.33, 4.56]) and SOT (aHR=2.49 [1.20, 4.96]).

267 Sensitivity analyses excluding patients without diagnosis code rankings did not qualitatively change
268 findings.

269

270 *Mechanical ventilation, and death in severe COVID-19 breakthrough illness*

271 Among the 249 hospitalized patients, a greater proportion of patients with CD4 counts <350
272 cells/mm³ required mechanical ventilation or died during hospitalization compared to PWH with higher CD4
273 counts and PWoH (Supplement **Figure 4**). No patients received ECMO.

274 Patients who needed mechanical ventilation (n=24) or died (n=33) were older (≥55 years), male, non-
275 Hispanic Black, had high proportions of comorbidities, and low uptake (10-13%) of additional vaccine doses
276 (**Supplemental Table 6**). Of those who had a known death during or within 30 days following COVID-19
277 hospitalization (n=33), the majority had comorbidities including obese BMI (68%), HTN (95%), DM (65%),

278 ESRD (30%), SOT (20%), RA (10%), or a cancer diagnosis (25%). Among PWH who died during a severe
279 COVID-19 breakthrough illness (n=12), 50% had a prior diagnosis of AIDS and their median CD4 count at
280 fully vaccinated was 352 (IQR 291, 423) cells/mm³.

281

282 **DISCUSSION**

283 Prior CIVETs collaboration analyses showed a 28% increase in breakthrough COVID-19 among PWH
284 compared with PWOH.⁴ Our present findings show the risk of severe illness (requiring hospitalization) after
285 COVID-19 breakthrough was low (7% of 3,649 vaccinated PWH and PWOH) and did not differ by HIV status
286 overall. PWH with lower CD4 counts (<350cells/mm³), however, had a 59% increase in the risk of severe
287 COVID-19 breakthrough illness compared to PWOH, suggesting a role of immune dysfunction in the
288 increased risk. The lack of difference in severe COVID-19 breakthrough illness risk between PWOH and
289 PWH with higher CD4 counts may be due to engagement in medical care, different healthcare seeking
290 behaviors and reduced comorbidities among the PWH included compared to PWOH. The increased risk of
291 severe COVID-19 breakthrough illness for PWH with moderate (CD4 200-349 cells/mm³) immune
292 suppression suggests they should be included with those who have advanced or untreated HIV in
293 recommendations for additional primary series vaccination doses, second booster doses, and counseled on
294 risk-reduction strategies.

295 Sex, age, comorbidities, and additional vaccine doses impact the risk of severe COVID-19
296 breakthrough illness.^{10,31-33} Among both PWOH and PWH, increasing age was the most significant risk factor
297 for severe COVID-19 breakthrough illness in our study. Female PWOH had reduced risk, which has been
298 previously documented;³⁴⁻³⁶ however, female PWH had increased severe risk. It is known that males and
299 females have distinct immune system responses with females often demonstrating increased immune
300 competence and less inflammatory immune responses, possibly contributing to their reduced risk for severe
301 COVID-19 breakthrough illness; however, immune dysfunction with HIV may alter this effect and requires
302 further investigation.^{34,37,38} Despite recommendations for additional COVID-19 vaccine doses being based in-
303 part on CD4 count,²⁵ we identified that the proportion of PWH who received additional doses varied little by
304 CD4 count and was likely driven by clinical decision making and patient preference.

305 Among PWOH, several comorbidities have been associated with increased severe COVID-19
306 breakthrough illness risk.^{32,33,39} Our findings suggest an increased risk with HTN, ESRD, and SOT.
307 Comorbidities were prevalent among those who experienced a severe COVID-19 breakthrough illness with
308 90% having a diagnosis of obesity, DM, HTN or ESRD. A lower proportion of PWH had at least one
309 comorbidity than PWOH (82% vs 94%), yet their severe COVID-19 breakthrough rates remained the same as
310 PWOH. Moderate to severe immune suppression from HIV itself is an important comorbidity that increases
311 severe COVID-19 breakthrough risk; additional comorbidities and a recent cancer diagnosis increased
312 severe COVID-19 breakthrough risk in PWH.

313

314 *Limitations*

315 Our findings may not be generalizable to all PWH, as our study population had a greater proportion of
316 males (89%) than found in the US population of PWH, and those with higher barriers to accessing healthcare
317 (who may be at greater risk for COVID-19) were less likely to be included in our study population. Other
318 outcome data, including mechanical ventilation and death (particularly if death occurred out of hospital) may
319 be under-ascertained. The discharge diagnosis ranking was not consistent as one cohort was only able to
320 provide the primary diagnosis with the remainder unranked; however, a sensitivity analyses demonstrated no
321 significant differences in results following exclusion of this cohort. All discharge diagnoses were reviewed by
322 clinicians to increase specificity in our classification of COVID-19 hospitalization, but discharge coding can be
323 influenced by many factors including reimbursement practices. Similarly, our matching schema was not
324 consistent, but the distributions of matching factors indicate that our sample of PWH and PWOH were
325 comparable; we included the matching factors in multivariable analyses to address residual confounding.

326

327 *Conclusions*

328 It was uncommon for COVID-19 breakthrough illness to progress to severe illness in our population of
329 PWH and PWOH; however, PWH with moderate immune suppression (200-349 cells/mm³) had an increased
330 severe COVID-19 breakthrough illness risk (compared to PWOH) and may benefit from being included in the
331 CDC's recommendation for those with "advanced and untreated HIV" to receive an additional dose in the

332 primary COVID-19 vaccination series and second booster vaccination. Clinicians should continue to promote
333 risk-reduction measures among PWH. The increased risk of severe COVID-19 breakthrough illness in PWH
334 with moderate and severe immune suppression merits ongoing surveillance to inform vaccine
335 recommendations as the pandemic persists, immunity to primary vaccine series and booster doses wane,
336 and new variants emerge.

337

338

339

Funding statement:

340 This project was made possible with supplemental funds to the North American AIDS Cohort Collaboration
341 on Research and Design (NA-ACCORD, U01AI069918) from the National Institute of Allergy and Infectious
342 Diseases (NIAID).

343

344 The NA-ACCORD is supported by National Institutes of Health grants U01AI069918, F31AI124794,
345 F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591,
346 K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763,
347 P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246,
348 R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, R34DA045592,
349 U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432,
350 U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067,
351 U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203,
352 U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242,
353 U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004,
354 UL1TR000083, UL1TR002378, UL1TR002489, Z01CP010214 and Z01CP010176; contracts CDC-200-2006-
355 18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, USA; contract
356 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health
357 Resources and Services Administration, USA; the Grady Health System; grants CBR-86906, CBR-94036,
358 HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of

359 Health and Long Term Care, and the Government of Alberta, Canada. Additional support was provided by
360 the National Institute Of Allergy And Infectious Diseases (NIAID), National Cancer Institute (NCI), National
361 Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute Of Child Health &
362 Human Development , National Human Genome Research Institute (NHGRI), National Institute for Mental
363 Health (NIMH) and National Institute on Drug Abuse (NIDA), National Institute On Aging (NIA), National
364 Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Neurological Disorders And
365 Stroke, National Institute Of Nursing Research (NINR), National Institute on Alcohol Abuse and Alcoholism
366 (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute
367 of Diabetes and Digestive and Kidney Diseases (NIDDK).

368

369 The content is solely the responsibility of the authors and does not necessarily represent the official views of
370 the National Institutes of Health, the US Centers for Disease Control and Prevention or the US Government
371 of Department of Veterans Affairs.

372

373 **Competing interests:**

374 KN Althoff reports grants from the National Institutes of Health (NIH, paid to institution) and consultancy to
375 the All of Us Research Program (NIH), TrioHealth, Kennedy Dundas, and MediQ (paid to her).

376

377 S Napravnik, LE Browne, JK Edwards, LS Park, MA Horberg, CR Jefferson, JM Certa, J Skarbinski report
378 grants from the NIH (paid to institution). KA Gebo reports grants from the NIH and Department of Defense
379 (paid to the institution). R Lang reports grants from CIHR, Alberta Innovates, and the University of Calgary
380 (paid to institution). VC Marconi has received investigator-initiated research grants (to the institution) and
381 consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV.

382

383 BC Hogan, SB Coburn, E Humes, W Leyden, C Stewart, E Watson, KS Gordon, AC Justice, MJ Silverberg,
384 DM Agil, KM Akgün, CF Williams report no conflicts of interest.

385

386 REFERENCES

- 387 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
388 Vaccine. *N Engl J Med*. Dec 31 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 389 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
390 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 391 3. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine
392 against Covid-19. *N Engl J Med*. Jun 10 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
- 393 4. Coburn SB, Humes E, Lang R, et al. COVID-19 infections post-vaccination by HIV status in the
394 United States. *medRxiv*. Dec 5 2021;doi:10.1101/2021.12.02.21267182
- 395 5. Sun J, Zheng Q, Madhira V, et al. Association Between Immune Dysfunction and COVID-19
396 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. *JAMA Intern Med*. Dec 28
397 2021;doi:10.1001/jamainternmed.2021.7024
- 398 6. Kim AHJ, Nakamura MC. COVID-19 Breakthrough Infection Among Immunocompromised Persons.
399 *JAMA Intern Med*. Dec 28 2021;doi:10.1001/jamainternmed.2021.7033
- 400 7. Yamamoto S, Maeda K, Matsuda K, et al. COVID-19 breakthrough infection and post-vaccination
401 neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching
402 study. *Clin Infect Dis*. Dec 24 2021;doi:10.1093/cid/ciab1048
- 403 8. Team CC-VBCI. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States,
404 January 1-April 30, 2021. *MMWR Morb Mortal Wkly Rep*. May 28 2021;70(21):792-793.
405 doi:10.15585/mmwr.mm7021e3
- 406 9. Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses
407 across a broad spectrum of immunocompromising conditions: the COVICS study. *Clin Infect Dis*. Feb 18
408 2022;doi:10.1093/cid/ciac103
- 409 10. Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2
410 infection after vaccination in a high-risk national population. *EClinicalMedicine*. Oct 2021;40:101117.
411 doi:10.1016/j.eclinm.2021.101117
- 412 11. Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North
413 Carolina. *N Engl J Med*. Mar 10 2022;386(10):933-941. doi:10.1056/NEJMoa2117128
- 414 12. Collins LF, Moran CA, Oliver NT, et al. Clinical characteristics, comorbidities and outcomes among
415 persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia. *AIDS*. Oct 1
416 2020;34(12):1789-1794. doi:10.1097/QAD.0000000000002632
- 417 13. Shalev N, Scherer M, LaSota ED, et al. Clinical Characteristics and Outcomes in People Living With
418 Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. *Clin Infect Dis*. Nov 19
419 2020;71(16):2294-2297. doi:10.1093/cid/ciaa635
- 420 14. Ceballos ME, Ross P, Lasso M, et al. Clinical characteristics and outcomes of people living with HIV
421 hospitalized with COVID-19: a nationwide experience. *Int J STD AIDS*. Apr 2021;32(5):435-443.
422 doi:10.1177/0956462420973106
- 423 15. Durstenfeld MS, Sun K, Ma Y, et al. Association of HIV infection with outcomes among adults
424 hospitalized with COVID-19. *AIDS*. Mar 1 2022;36(3):391-398. doi:10.1097/QAD.0000000000003129
- 425 16. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-
426 based cohort analysis of UK primary care data and linked national death registrations within the
427 OpenSAFELY platform. *Lancet HIV*. Jan 2021;8(1):e24-e32. doi:10.1016/S2352-3018(20)30305-2
- 428 17. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 Outcomes Among Persons Living With or
429 Without Diagnosed HIV Infection in New York State. *JAMA Netw Open*. Feb 1 2021;4(2):e2037069.
430 doi:10.1001/jamanetworkopen.2020.37069
- 431 18. Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-
432 19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. *Lancet HIV*.
433 Nov 2021;8(11):e690-e700. doi:10.1016/S2352-3018(21)00239-3
- 434 19. Dong Y, Li Z, Ding S, et al. HIV infection and risk of COVID-19 mortality: A meta-analysis. *Medicine*
435 (*Baltimore*). Jul 2 2021;100(26):e26573. doi:10.1097/MD.00000000000026573
- 436 20. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in
437 HIV/AIDS patients: a systematic review. *HIV Med*. Oct 2020;21(9):567-577. doi:10.1111/hiv.12911

- 438 21. Hoffmann C, Casado JL, Harter G, et al. Immune deficiency is a risk factor for severe COVID-19 in
439 people living with HIV. *HIV Med.* May 2021;22(5):372-378. doi:10.1111/hiv.13037
- 440 22. Lesko CR, Bengtson AM. HIV and COVID-19: Intersecting Epidemics With Many Unknowns. *Am J*
441 *Epidemiol.* Jan 4 2021;190(1):10-16. doi:10.1093/aje/kwaa158
- 442 23. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients
443 with HIV: a multicentre research network study. *AIDS.* Nov 1 2020;34(13):F3-F8.
444 doi:10.1097/QAD.0000000000002666
- 445 24. Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely
446 Immunocompromised People Updated Feb 17, 2022. Accessed March 14, 2021.
447 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>
- 448 25. Centers for Disease Control and Prevention (CDC). COVID-19 and HIV. Accessed March 31, 2022.
449 <https://www.cdc.gov/hiv/covid-19/index.html>
- 450 26. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS Cohort
451 Collaboration on Research and Design (NA-ACCORD). *Int J Epidemiol.* Apr 2007;36(2):294-301.
452 doi:10.1093/ije/dyl286
- 453 27. When You've Been Fully Vaccinated | CDC. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html>. Accessed January 4, 2022.
- 454 28. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the
455 National VA Health Information System. *Med Care.* Aug 2006;44(8 Suppl 2):S25-30.
456 doi:10.1097/01.mlr.0000223670.00890.74
- 457 29. Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR) | CDC.
458 <https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html>. Accessed January 4, 2022.
- 459 30. Centers for Disease Control and Prevention. AIDS-Defining Conditions. MMWR Recommendations
460 and Reports. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm> Published December 5, 2008.
461 Accessed January 4, 2021.
- 462 31. Botton J, Semenzato L, Jabagi MJ, et al. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2
463 Vaccine for COVID-19 Hospitalizations. *JAMA Netw Open.* Mar 1 2022;5(3):e220868.
464 doi:10.1001/jamanetworkopen.2022.0868
- 465 32. Wright BJ, Tideman S, Diaz GA, French T, Parsons GT, Robicsek A. Comparative vaccine
466 effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
467 *Lancet Respir Med.* Feb 25 2022;doi:10.1016/S2213-2600(22)00042-X
- 468 33. Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection
469 against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in
470 Italy: retrospective cohort study. *BMJ.* Feb 10 2022;376:e069052. doi:10.1136/bmj-2021-069052
- 471 34. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more
472 vulnerable? *Biol Sex Differ.* Sep 18 2020;11(1):53. doi:10.1186/s13293-020-00330-7
- 473 35. Vahidy FS, Pan AP, Ahnstedt H, et al. Sex differences in susceptibility, severity, and outcomes of
474 coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. *PLoS One.*
475 2021;16(1):e0245556. doi:10.1371/journal.pone.0245556
- 476 36. Liu C, Lee J, Ta C, et al. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough
477 Infections - Risk Factors and Vaccine Effectiveness. *medRxiv.* Oct 7 2021;doi:10.1101/2021.10.05.21264583
- 478 37. Strandberg TE, Pentti J, Kivimaki M. Sex Difference in Serious Infections: Not Only COVID-19.
479 *Epidemiology.* Nov 1 2021;32(6):e26-e27. doi:10.1097/EDE.0000000000001408
- 480 38. Qi S, Ngwa C, Morales Scheihing DA, et al. Sex differences in the immune response to acute COVID-
481 19 respiratory tract infection. *Biol Sex Differ.* Dec 20 2021;12(1):66. doi:10.1186/s13293-021-00410-2
- 482 39. Butt AA, Yan P, Shaikh OS, Mayr FB, Omer SB. Rate and Risk Factors for Severe/Critical Disease
483 Among Fully Vaccinated Persons with Breakthrough SARS-CoV-2 Infection in a High-risk National
484 Population. *Clin Infect Dis.* Dec 10 2021;doi:10.1093/cid/ciab1023
- 485
486

Table 1: Characteristics at date of SARS-CoV-2 breakthrough infection, N=3,649

Characteristic	PWoH, N = 2,408 ¹	PWH, N = 1,241 ¹
Hospitalization	170 (7%)	79 (6%)
Mechanical Ventilation among those hospitalized	16 (9%)	8 (10%)
Death among breakthrough infections	21 (1%)	12 (1%)
Age		
18-24	9 (0%)	9 (1%)
25-34	137 (6%)	112 (9%)
35-44	279 (12%)	184 (15%)
45-54	492 (20%)	245 (20%)
55-64	797 (33%)	359 (29%)
65-74	539 (22%)	264 (21%)
75+	155 (6%)	68 (6%)
Sex		
Male	2,108 (88%)	1,136 (92%)
Female	300 (13%)	105 (9%)
Ethnicity and Race		
Non-Hispanic white	744 (31%)	421 (34%)
Non-Hispanic Black/African American	1,151 (48%)	555 (45%)
Hispanic	366 (15%)	183 (15%)
Other	131 (5%)	71 (6%)
Unknown	16 (1%)	11 (1%)
Month of breakthrough		
Jan-June	247 (10%)	134 (11%)
July-Oct	1,132 (47%)	639 (51%)
Nov-Dec	1,029 (43%)	468 (38%)
Primary vaccination series type		
Pfizer	1,194 (50%)	605 (49%)
Pfizer + 3rd dose	194 (8%)	165 (13%)
Moderna	676 (28%)	301 (24%)
Moderna + 3rd dose	95 (4%)	68 (6%)
J&J	234 (10%)	93 (7%)
J&J + 2nd dose	15 (1%)	9 (1%)
COVID prior to fully vaccinated	292 (12%)	176 (14%)
Comorbidities at fully vaccinated		
Obese BMI (≥ 30 kg/m ²)	1,218 (54%)	434 (36%)

Characteristic	PWoH, N = 2,408 ¹	PWH, N = 1,241 ¹
Diabetes	817 (34%)	308 (25%)
Hypertension	1,443 (60%)	633 (51%)
End-stage renal disease	63 (3%)	38 (3%)
Immune suppressive conditions at fully vaccinated		
Organ or tissue transplantation	43 (2%)	18 (2%)
Rheumatoid arthritis	44 (2%)	14 (1%)
Lupus	10 (0%)	3 (0%)
Cancer diagnosis	187 (8%)	129 (10%)
Pregnancy	4 (0%)	3 (0%)
CD4 at ART initiation (cells/mm³)		393(234, 613)
unknown		536 (43%)
AIDS before fully vaccinated		325 (26%)
CD4 at fully vaccinated (cells/mm³)		620 (438, 846)
<200		54 (4%)
200-349		109 (9%)
350-499		182 (15%)
≥500		707 (57%)
unknown		189 (15%)
Suppressed HIV RNA at fully vaccinated (<50 copies/mL)		1,016 (91%)
unknown		120 (10%)

¹n (%) except for CD4 counts where the medians (interquartile ranges) are reported


Definitions:

- Death defined as died while hospitalized for COVID-19 or within 30 days following discharge or within 30 days of COVID-19 diagnosis among those not hospitalized.
- Mechanical Ventilation: Measured during the dates of hospital admission and discharge.
- Age was categorized in 5-year increments for descriptive purposes
- BMI, Diabetes, Hypertension, ESRD, Organ or tissue transplantation, RA, Lupus: Measured as close to the date fully vaccinated as possible within the window of 10/1/2015 – date fully vaccinated.
- Cancer, Pregnancy: Measured as close to the date fully vaccinated as possible within the window of 1/1/2020 – date fully vaccinated
- AIDS was defined using clinical diagnosis codes of AIDS-defining conditions.

Abbreviations:

AIDS, acquired immunodeficiency syndrome
 ART, antiretroviral Therapy
 BMI, body mass index
 COVID-19, Coronavirus Disease 2019
 ESRD, end-stage renal disease
 HIV, human immunodeficiency virus
 PWH, people with HIV
 PWoH, people without HIV
 RA, rheumatoid arthritis

Figure 1: Incidence Rates of Severe COVID-19 breakthrough per 100 patient-years (PY) in people with and without HIV by month (along with 95% CI) (N=3,649)




Footnote:

The incidence rate estimates for January 2021 were not estimated as there were 0 and 0.02 person-years of observation after COVID-19 breakthrough infection in PWH and PWoH, respectively. Similarly, the person years in February 2021 were 0.14 and 0.21 in PWH and PWoH (respectively) and there were no severe COVID-19 breakthrough illness events; incidence rates were not estimated.

Figure 2: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading), stratified by a) HIV status, b) CD4 count and HIV status, and c) HIV viral suppression and HIV status


a) severe COVID-19 breakthrough illness, by HIV status



Footnotes:
Log-rank test $p=0.399$.

b) severe COVID-19 breakthrough illness, by CD4 count and HIV status

Cumulative incidence of hospitalization



Number at risk

CD4		0	7	14	21	28
	PWoH	2408	1775	1532	1442	1402
	PWH, CD4 < 350	163	128	113	109	108
	PWH, CD4 >= 350	889	678	598	583	564
		0	7	14	21	28

Time since breakthrough date (days)


Footnotes:

Log-rank test including PWoH: $p < 0.001$.

Log-rank test after excluding PWoH: $p < 0.001$.

c) severe COVID-19 breakthrough illness, by HIV viral suppression and HIV status

Cumulative incidence of hospitalization



Number at risk

VL	0	7	14	21	28
Unsuppressed viral load	105	88	76	73	69
Suppressed viral load	1016	770	680	663	647
PWoH	2408	1775	1532	1442	1402

Footnotes:


Log-rank test including PWoH: $p=0.309$.

Log-rank test after excluding PWoH: $p=0.284$.

Virally suppressed defined by HIV-1 RNA viral load <50 copies/mL.

Figure 3: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading), stratified by HIV status and primary vaccination series type

a) By primary vaccination series type




Footnotes:

Log rank test for J&J: p=0.404

Log rank test for Pfizer: p=0.665

Log rank test for Moderna: p=0.15

b) By primary series and additional vaccine doses



Number at risk

	0	7	14	21	28
PWoH –Primary series only	2104	1653	1470	1394	1364
PWH –Primary series only	999	827	766	756	739
PWoH –Primary series + additional dose	304	122	62	48	38
PWH –Primary series + additional dose	242	123	71	60	55
	0	7	14	21	28

Footnotes:
Log rank test: p=0.021

Table 2: Crude (HR) and adjusted hazard ratios (aHR) and 95% confidence intervals (CI) of severe SARS-CoV-2 breakthrough illness

HIV status	Total Population (N=3,385)			
	HR (95% CI)		^a aHR (95% CI)	
PWoH	1.00		1.00	
PWH, CD4 count <350cells/mm ³	2.00 (1.26, 3.02)		1.59 (0.99, 2.46)	
PWH, CD4 count ≥350cells/mm ³	0.70 (0.50, 0.97)		0.95 (0.67, 1.32)	
Characteristics	^a PWoH (N=2,350 n=170)		^b PWH (N=1,035 n=68)	
	HR (95% CI)	aHR (95% CI)	HR (95% CI)	aHR (95% CI)
Sex				
Male	1.00	1.00	1.00	1.00
Female	0.25 (0.10, 0.52)	0.48 (0.16, 1.12)	1.50 (0.66, 2.95)	2.88 (1.03, 7.11)
Ethnicity and Race				
Non-Hispanic white		1.00	1.00	1.00
Non-Hispanic Black/African American	1.24 (0.88, 1.77)	1.26 (0.86, 1.85)	1.26 (0.73, 2.22)	1.26 (0.70, 2.32)
Hispanic	1.01 (0.61, 1.62)	1.21 (0.72, 1.98)	0.98 (0.43, 2.10)	1.54 (0.65, 3.38)
Other/Unknown	0.52 (0.18, 1.19)	1.24 (0.43, 2.86)	1.30 (0.43, 3.21)	2.71 (0.87, 7.12)
Age				
<55	1.00	1.00	1.00	1.00
55-64	6.63 (3.54, 13.80)	3.49 (1.74, 7.86)	3.02 (1.52, 6.33)	2.11 (0.98, 4.80)
65-74	12.60 (6.82, 26.00)	5.37 (2.64, 12.20)	4.41 (2.25, 9.13)	3.01 (1.37, 6.98)
75+	21.00 (10.70, 45.00)	8.44 (3.90, 20.00)	7.71 (3.25, 17.9)	5.21 (1.88, 14.40)
Primary vaccination series type				
Primary Series only	1.00	1.00	1.00	1.00
Primary Series + additional dose	0.63 (0.34, 1.07)	0.56 (0.29, 0.98)	0.43 (0.17, 0.91)	0.47 (0.18, 1.04)
COVID-19 prior to fully vaccinated	0.39 (0.18, 0.71)	0.21 (0.09, 0.40)	0.43 (0.15, 0.97)	0.22 (0.07, 0.52)
Calendar period of breakthrough				
Jan – June	1.00		1.00	
July – Oct	1.49 (0.91, 2.62)		2.53 (1.03, 8.40)	
Nov – Dec	0.77 (0.45, 1.40)		1.41 (0.53, 4.89)	
Comorbidities before fully vaccinated				
Obese BMI (≥30 kg/m ² vs. <30)	0.98 (0.72, 1.34)	1.01 (0.73, 1.40)	1.38 (0.85, 2.23)	1.46 (0.85, 2.49)
Diabetes (vs. no)	2.80 (2.07, 3.81)	1.11 (0.79, 1.56)	2.26 (1.39, 3.64)	1.47 (0.85, 2.50)
Hypertension (vs. no)	7.73 (4.65, 14.00)	4.51 (2.35, 9.80)	3.02 (1.78, 5.39)	1.27 (0.67, 2.50)
End-stage renal disease (vs. no)	6.25 (3.88, 9.58)	2.53 (1.33, 4.56)	1.82 (0.55, 4.41)	1.12 (0.31, 3.09)
Immune suppressive conditions at fully vaccinated (vs. no)				
Organ or tissue transplantation	6.79 (3.89, 11.0)	2.49 (1.20, 4.96)	0.95 (0.05, 4.27)	0.55 (0.03, 3.39)
Rheumatoid arthritis	2.03 (0.80, 4.19)	1.33 (0.50, 2.87)	1.28 (0.07, 5.78)	1.09 (0.06, 5.45)
Cancer diagnosis	2.64 (1.75, 3.86)	1.47 (0.95, 2.19)	2.92 (1.64, 4.95)	1.97 (1.05, 3.51)
Lupus ^c	2.86 (0.47, 8.95)			
AIDS diagnosis before fully vaccinated			1.83 (1.11, 2.96)	1.22 (0.70, 2.10)
HIV RNA at fully vaccinated				
Suppressed (<50 copies/mL)			1.00	
Unsuppressed (≥50 copies/mL)			1.43 (0.66, 2.74)	
CD4 count at fully vaccinated (cells/mm³)				
≥500			1.00	1.00
350-499			1.28 (0.62, 2.44)	1.19 (0.56, 2.35)
200-349			2.52 (1.28, 4.66)	1.65 (0.80, 3.21)
<200			3.98 (1.86, 7.76)	2.57 (1.15, 5.29)

Footnotes:

Total number of severe COVID-19 illness events=238.

Abbreviations: HR=crude hazard ratio. aHR=adjusted hazard ratio. 95% CI=95% confidence interval.

^aAdjusted for age (categorized into a 4-level group to assess a dose response relationship among older people (i.e., 55+) that are known to be at greater risk), sex, race and ethnicity, primary vaccination series type, COVID-19 prior to fully vaccinated, Comorbidities before fully vaccinated, immune suppressive conditions at fully vaccinated, and cohort.

^b Adjusted for the covariates in the table and cohort. 184(15.1% of all PWH) were excluded due to missing CD4 or HIV RNA measurements.

^c There were no severe COVID-19 breakthrough illnesses among PWH with lupus, and it was therefore excluded from the multivariable model.

Values with P<0.05 are bolded.

SUPPLEMENT

Supplement Table 1: Definitions of in care and criteria used to identify people with (PWH) and without HIV (PWoH)

Cohort	Description	“In care” or “in cohort”	PWH
Kaiser Permanente Mid-Atlantic States (KPMAS)	Integrated Health system	In Care – KPMAS membership for ≥1 month in 2020	HIV registry*
Kaiser Permanente Northern California (KPNC)	Integrated Health system	In Care – KPNC membership for ≥1 month between 3/1/20 and 12/31/20	HIV registry*
University of North Carolina Chapel Hill (UNC)	Medical center cohort	≥1 encounter with UNC Health in 2019 and alive as of 03/01/2020	HIV diagnosis (by ICD diagnosis code)
Veterans Aging Cohort Study (VACS)	National cohort of all PWH and 1:2 demographically-matched PWoH in care in the Veterans Health Administration (VA) system	Enrolled in VACS from 1996-2017 and alive in 2020	HIV diagnosis (presence of 1 inpatient or 2 outpatient ICD codes for HIV)

The Kaiser Permanente Mid-Atlantic States and Northern California HIV Registries are databases of members diagnosed with HIV since 1998 and 1980, respectively. Primary sources used to identify HIV patients are HIV-specific laboratory tests, antiretroviral therapy, hospital-based HIV diagnosis, and diagnosis.

Supplement Table 2: Diagnosis and Procedure codes used to ascertain comorbidities and outcomes

Condition	ICD-10 Diagnosis Codes
COVID-19 breakthrough infection Between Jan 1, 2020 -Dec 31, 2021	U07.1 (specific to COVID), B34.2 (Coronavirus infection, unspecified), B97.21 (SARS-associated coronavirus causing disease classified elsewhere), B97.29 (other coronavirus as the cause of diseases classified elsewhere, J12.81 (pneumonia due to SARS-associated coronavirus, or O98.5 COVID in pregnancy, child-birth or postpartum
Immune suppressive Conditions	
Organ or tissue transplantation	Z94.x
Rheumatoid Arthritis	M05, M06
Lupus	M32
Cancer	C00-C14, C15-C26, C30-C39, C40-C41, C43-C44, C45-C49, C50, C51-C58, C60-C63, C64-C68, C69-C72, C73-C75, C76-C80, C81-C96, C7A, C7B, D45
Pregnancy	Z3A, O00-O16, O20-O48, O60-O77, O80-O82, O94-O9A
Comorbidities	
Diabetes	E11.x
End stage renal disease	N18.5 CKD stage 5, N18.6 ESRD
Hypertension	I10-I15.9, I67.4)
Obesity	E66.x, O99.21x
Outcomes of COVID-19 Hospitalization	
Mechanical Ventilation	<p>ICD-10 procedure codes: 0BH17EZ: Intubation 5A1945Z: Respiratory Ventilation, 24-96 Consecutive Hours 5A1955Z: Respiratory Ventilation, Greater than 96 Consecutive Hours 5A1935Z: Respiratory Ventilation, Less than 24 Consecutive Hours 5A1522G: Extracorporeal Oxygenation, Perph VA ECMO 5A15A2G: Extracorporeal Oxygenation, Perph VA ECMO, Intraop 5A15A2H: Extracorporeal Oxygenation, Perph VV ECMO, Intraop</p> <p>CPT codes: 94002: HC Ventilation Assist & Mgmt Inpatient 1st day 94003: HC Ventilation Assist & Mgmt Inpatient subsequent days</p>

Supplement Table 3: Proportion of PWH who received additional vaccine doses by CD4 count at fully vaccinated (N=1,241).

CD4 at fully vaccinated (cells/mm³)	# of COVID-19 breakthroughs in PWH	# who received an additional COVID-19 vaccine
<200	54	9 (17%)
200-349	109	17 (16%)
350-499	182	41 (23%)
≥500	707	141 (20%)
Unknown	189	34 (18%)


Supplement Table 4: Characteristics of SARS-CoV-2 breakthrough infection, both severe and non-severe by HIV status N=3,649

Characteristic	PWoH N=2,408		PWH N=1,241	
	No Severe Breakthrough N = 2,238	Severe Breakthrough N = 170	No Severe Breakthrough N = 1,162	Severe Breakthrough N = 79
Age (years)				
<55	907 (41%)	10 (6%)	534 (46%)	16 (20%)
55-64	741 (33%)	56 (33%)	333 (28%)	26 (33%)
65-74	486 (21%)	71 (42%)	240 (21%)	24 (30%)
75+	122 (5%)	33 (19%)	55 (5%)	13 (16%)
Sex				
Male	1944 (87%)	164 (97%)	1,065 (91%)	71 (90%)
Female	294 (13%)	6 (4%)	97 (8%)	8 (10%)
Ethnicity and Race				
Non-Hispanic White	694 (31%)	50 (29%)	397 (34%)	24 (30%)
Non-Hispanic Black/ African American	1,060 (47%)	91 (54%)	515 (44%)	40 (51%)
Hispanic	342 (15%)	24 (14%)	173 (15%)	10 (13%)
Other	127 (6%)	4 (3%)	66 (6%)	5 (6%)
Unknown	15 (1%)	1 (1%)	11 (1%)	0 (0.0%)
Month of breakthrough				
Jan-June	231 (10%)	16 (9%)	129 (11%)	5 (6%)
July-Oct	1,024 (46%)	108 (64%)	585 (50%)	54 (68%)
Nov-Dec	983 (44%)	46 (27%)	448 (39%)	20 (25%)
Vaccine series				
Pfizer	1,103 (49%)	91 (54%)	559 (48%)	46 (58%)
Pfizer + 3rd dose	187 (8%)	7 (4%)	160 (14%)	5 (6%)
Moderna	629 (28%)	47 (28%)	285 (25%)	16 (20%)
Moderna + 3rd dose	90 (4%)	5 (3%)	67 (6%)	1 (1%)
J&J	215 (10%)	19 (11%)	82 (7%)	11 (14%)
J&J + 2 nd dose	14 (1%)	1 (1%)	9 (1%)	0 (0%)
COVID prior to full vaccination date	283 (13%)	9 (5%)	170 (15%)	6 (8%)
Comorbidities before fully vaccinated				
Obese BMI (≥ 30 kg/m ²)	1,132 (54%)	86 (53%)	402 (36%)	32 (43%)
Diabetes	718 (32%)	99 (58%)	276 (24%)	32 (41%)
Hypertension	1,287 (58%)	156 (92%)	577 (50%)	56 (71%)
End-stage renal disease	41 (2%)	22 (13%)	34 (3%)	4 (5%)
Organ or tissue transplantation	27 (1%)	16 (9%)	17 (1%)	1 (1%)
Rheumatoid arthritis	38 (2%)	6 (4%)	13 (1%)	1 (1%)
Lupus	8 (0%)	2 (1%)	3 (0%)	0 (0%)

Characteristic	PWoH N=2,408		PWH N=1,241	
	No Severe Breakthrough N = 2,238	Severe Breakthrough N = 170	No Severe Breakthrough N = 1,162	Severe Breakthrough N = 79
Cancer diagnosis	157 (7%)	30 (18%)	111 (10%)	18 (23%)
Pregnancy	4 (0%)	0 (0%)	3 (0%)	0 (0%)

Age was categorized into a 4-level group to assess a dose response relationship among older people (i.e., 55+) that are known to be at greater risk.

Supplement Figure 1: Identification of severe COVID-19 breakthrough infections



Supplement Table 5: Severe COVID-19 breakthrough illness Incidence rates and 95% confidence intervals, by month and HIV status


	# of severe COVID-19 breakthroughs	# of person-years	IR (95% CI) per 100 person years
Total			
Overall	249	191.3	137.5 (117.6, 159.8)
PWH	79	67.7	116.7 (92.4, 145.4)
PWoH	170	123.6	130.2 (114.5, 147.4)
Moderna			
Overall	69	61.9	111.5 (86.8, 141.2)
PWH	17	21.0	81.1 (47.3, 129.9)
PWoH	52	40.9	127.1 (94.9, 166.7)
Pfizer			
Overall	149	110.3	135.1 (114.3, 158.7)
PWH	51	41.1	124.1 (92.4, 163.2)
PWoH	98	69.2	141.7 (115.0, 172.7)
J&J			
Overall	31	19.2	161.5 (109.7, 229.2)
PWH	11	5.7	194.4 (97.0, 347.8)
PWoH	20	13.5	147.8 (90.2, 228.2)

By calendar month				
Jan	Overall	0	0.02	0.0 (0.0, 19248.5)
	PWH	0	0	n/a
	PWoH	0	0.02	0.0 (0.0, 19248.1)
Feb	Overall	0	0.35	0.00 (0.00, 1052.6)
	PWH	0	0.14	0.0 (0.0, 2641.9)
	PWoH	0	0.21	0.0 (0.0, 1749.8)
Mar	Overall	2	2.56	78.2 (9.5, 282.5)
	PWH	0	0.90	0.0 (0.0, 409.5)
	PWoH	2	1.66	120.7 (14.6, 436.2)
Apr	Overall	6	6.06	99.0 (36.3, 215.5)
	PWH	1	2.13	47.0 (1.2, 261.6)
	PWoH	5	3.93	127.2 (41.3, 296.8)
May	Overall	8	9.07	88.2 (38.1, 173.8)
	PWH	3	3.13	95.8 (19.8, 272.9)
	PWoH	5	5.94	84.2 (27.3, 196.5)
June	Overall	3	7.33	41.0 (8.4, 119.7)
	PWH	1	2.52	39.7 (1.0, 221.2)
	PWoH	2	4.81	41.6 (5.0, 150.3)
Jul	Overall	16	13.25	120.7 (69.0, 196.1)
	PWH	4	5.60	71.4 (19.5, 182.7)
	PWoH	12	7.65	156.9 (81.1, 274.1)
Aug	Overall	69	44.68	154.4 (120.2, 195.4)
	PWH	25	19.2	130.2 (84.3, 192.2)
	PWoH	44	25.5	172.7 (125.5, 231.8)
Sept	Overall	57	42.40	134.5 (101.8, 174.2)
	PWH	18	13.9	129.9 (77.0, 205.3)
	PWoH	39	28.5	136.7 (97.2, 186.8)
	Overall	20	29.25	68.4 (41.8, 105.6)


Oct	PWH	7	9.5	74.1 (29.8, 152.7)
	PWoH	13	19.8	65.7 (35.0, 112.3)
Nov	Overall	24	19.15	125.3 (80.3, 186.5)
	PWH	7	6.0	117.3 (47.2, 241.8)
	PWoH	17	13.2	128.9 (75.1, 206.4)
Dec	Overall	44	36.67	120.0 (87.2, 161.1)
	PWH	13	11.4	114.4 (60.9, 195.7)
	PWoH	31	25.3	122.5 (83.2, 173.8)

Supplement Figure 2: Histograms of the date of severe SARS-CoV-2 breakthrough infection, by HIV status


a) Calendar time



b) Time from date fully vaccinated to breakthrough



Supplemental Figure 3: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading) stratified by CD4 count and HIV status



Log-rank test: $p < 0.001$

Supplement Table 6: Characteristics of participants with breakthrough COVID-19 illness requiring hospitalization, mechanical ventilation or in those who died

Characteristic	Hospitalized (Severe COVID-19) N = 249	Mechanical ventilation N = 24	Death N = 20
HIV Status			
PWoH	170 (68%)	16 (67%)	14 (70%)
PWH	79 (32%)	8 (33%)	6 (30%)
Age (years)			
<55	19 (8%)	3 (13%)	2 (10%)
55-64	82 (33%)	9 (38%)	4 (20%)
65-74	95 (38%)	6 (25%)	5 (25%)
75+	46 (19%)	6 (25%)	9 (45%)
Sex			
Male	235 (94%)	20 (83%)	18 (90%)
Female	14 (6%)	4 (17%)	2 (10%)
Ethnicity and Race			
Non-Hispanic White	74 (30%)	2 (8%)	5 (25%)
Non-Hispanic Black/African American	131 (53%)	18 (75%)	11 (55%)
Hispanic	34 (14%)	4 (17%)	4 (20%)
Other	9 (4%)	0 (0%)	0 (0%)
Unknown	1 (0%)	0 (0%)	0 (0%)
Month of breakthrough			
Jan-June	21 (8%)	3 (13%)	3 (15%)
July-Oct	162 (65%)	16 (67%)	13 (65%)
Nov-Dec	66 (27%)	5 (21%)	4 (20%)
COVID prior to vaccination	15 (6%)	0 (0%)	0 (0%)
Vaccine Series			
Primary Series Only	230 (92%)	21 (88%)	18 (90%)

Characteristic	Hospitalized (Severe COVID-19) N = 249	Mechanical ventilation N = 24	Death N = 20
Primary Series + additional dose	19 (8%)	3 (13%)	2 (10%)
Obese BMI (>=30 kg/m²)	118 (50%)	20 (87%)	13 (68%)
Unknown	13	1	1
Diabetes	131 (53%)	15 (63%)	13 (65%)
Hypertension	212 (85%)	23 (96%)	19 (95%)
End-stage renal disease	26 (10%)	5 (21%)	6 (30%)
Organ or tissue transplantation	17 (7%)	5 (21%)	4 (20%)
Rheumatoid arthritis	7 (3%)	3 (13%)	2 (10%)
Lupus	2 (1%)	0 (0%)	0 (0%)
Cancer diagnosis	48 (19%)	5 (21%)	5 (25%)
CD4 at ART initiation	399 (212,546)	376 (324,417)	398 (354,855)
Unknown	210	20	15
AIDS before fully vaccinated	29 (37%)	3 (38%)	3 (50%)
Unknown	170	16	14
CD4 at fully vaccinated	498 (305,746)	352 (172,542)	352 (291,423)
Unknown	181	18	16
Suppressed HIV RNA at fully vaccinated	59 (87%)	5 (83%)	4 (100%)
Unknown	181	18	16

n(%); median (IQR)

Supplement Figure 4: Outcomes of breakthrough illness among those hospitalized after fully vaccinated to Dec 31, 2021, by HIV status (n=170 PWOH) and CD4 count (n=23 <350 cells/mm³ and n=45 ≥350 cells/mm³) among PWH

